-
Je něco špatně v tomto záznamu ?
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
M. Salmon, HE. White, H. Zizkova, A. Gottschalk, E. Motlova, N. Cerveira, D. Colomer, D. Coriu, GN. Franke, E. Gottardi, B. Izzo, T. Jurcek, T. Lion, V. Schäfer, C. Venturi, P. Vigneri, M. Zawada, J. Zuna, L. Hovorkova, J. Koblihova, H. Klamova,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- bcr-abl fúzové proteiny * genetika MeSH
- chronická myeloidní leukemie * diagnóza farmakoterapie genetika MeSH
- imatinib mesylát MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidé MeSH
- reziduální nádor genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10). We found the amplification ratio of the e13a2 amplicon was 38% greater than e14a2 (p = 0.015), and the amplification efficiency was 2% greater (P = 0.17). This subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n = 67) compared to e14a2 (n = 78) when analysed by RT-qPCR (P = 0.0005) but not ddPCR (P = 0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type; these differences are small but may need to be considered for optimal patient management.
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 University of Jena Jena Germany
Faculty of Medicine University of Southampton Southampton UK
Fundeni Clinical Institute Hematology Department Bucharest Romania
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCSS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy
Labdia Labordiagnostik St Anna Children ́s Cancer Research Institute Vienna Austria
Laboratory of Chemical and Clinical Analysis Area 3 A O U San Luigi Gonzaga Orbassano Turin Italy
National Center for Tumor Diseases Heidelberg Germany
Portuguese Oncology Institute of Porto Porto Portugal
The University Hospital in Krakow Krakow Poland
Wessex Regional Genetics Laboratory Salisbury NHS Foundation Trust Salisbury UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025346
- 003
- CZ-PrNML
- 005
- 20221031100154.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-022-01612-2 $2 doi
- 035 __
- $a (PubMed)35676453
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Salmon, Matthew $u Faculty of Medicine, University of Southampton, Southampton, UK $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK
- 245 10
- $a Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy / $c M. Salmon, HE. White, H. Zizkova, A. Gottschalk, E. Motlova, N. Cerveira, D. Colomer, D. Coriu, GN. Franke, E. Gottardi, B. Izzo, T. Jurcek, T. Lion, V. Schäfer, C. Venturi, P. Vigneri, M. Zawada, J. Zuna, L. Hovorkova, J. Koblihova, H. Klamova, MS. Markova, D. Srbova, A. Benesova, V. Polivkova, D. Zackova, J. Mayer, I. Roeder, I. Glauche, T. Ernst, A. Hochhaus, KM. Polakova, NCP. Cross
- 520 9_
- $a Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::ABL1 have a faster molecular response to therapy compared to patients expressing e13a2. To explore the reason for this difference we undertook a detailed technical comparison of the commonly used Europe Against Cancer (EAC) BCR::ABL1 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay in European Treatment and Outcome Study (EUTOS) reference laboratories (n = 10). We found the amplification ratio of the e13a2 amplicon was 38% greater than e14a2 (p = 0.015), and the amplification efficiency was 2% greater (P = 0.17). This subtle difference led to measurable transcript-type dependent variation in estimates of residual disease which could be corrected by (i) taking the qPCR amplification efficiency into account, (ii) using alternative RT-qPCR approaches or (iii) droplet digital PCR (ddPCR), a technique which is relatively insensitive to differences in amplification kinetics. In CML patients, higher levels of BCR::ABL1/GUSB were identified at diagnosis for patients expressing e13a2 (n = 67) compared to e14a2 (n = 78) when analysed by RT-qPCR (P = 0.0005) but not ddPCR (P = 0.5). These data indicate that widely used RT-qPCR assays result in subtly different estimates of disease depending on BCR::ABL1 transcript type; these differences are small but may need to be considered for optimal patient management.
- 650 12
- $a bcr-abl fúzové proteiny $x genetika $7 D016044
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $7 D000068877
- 650 12
- $a chronická myeloidní leukemie $x diagnóza $x farmakoterapie $x genetika $7 D015464
- 650 _2
- $a reziduální nádor $x genetika $7 D018365
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a White, Helen E $u Faculty of Medicine, University of Southampton, Southampton, UK $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK
- 700 1_
- $a Zizkova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Gottschalk, Andrea $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany
- 700 1_
- $a Motlova, Eliska $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Cerveira, Nuno $u Portuguese Oncology Institute of Porto, Porto, Portugal
- 700 1_
- $a Colomer, Dolors $u Pathology Department, Hospital Clinic, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain $1 https://orcid.org/http://orcid.org/0000000174868484
- 700 1_
- $a Coriu, Daniel $u Fundeni Clinical Institute, Hematology Department, Bucharest, Romania $u Hematology Department, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
- 700 1_
- $a Franke, Georg N $u University of Leipzig Medical Center, Department for Hematology, Cellular Therapies and Hemostaseology, Leipzig, Germany $1 https://orcid.org/http://orcid.org/000000018239002X
- 700 1_
- $a Gottardi, Enrico $u Laboratory of Chemical and Clinical Analysis "Area 3" A.O.U San Luigi Gonzaga-Orbassano, Turin, Italy
- 700 1_
- $a Izzo, Barbara $u Department of Molecular Medicine and Medical Biotechnology University 'Federico II' and CEINGE - Advanced Biotechnologies, Naples, Italy $1 https://orcid.org/http://orcid.org/0000000270210367
- 700 1_
- $a Jurcek, Tomas $u Center of Molecular Biology and Gene Therapy, Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Lion, Thomas $u Labdia Labordiagnostik / St. Anna Children ́s Cancer Research Institute (CCRI), Vienna, Austria
- 700 1_
- $a Schäfer, Vivien $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany
- 700 1_
- $a Venturi, Claudia $u IRCSS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
- 700 1_
- $a Vigneri, Paolo $u University of Catania, Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, Catania, Italy
- 700 1_
- $a Zawada, Magdalena $u The University Hospital in Krakow, Krakow, Poland
- 700 1_
- $a Zuna, Jan $u CLIP, Dept. of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000208873709
- 700 1_
- $a Hovorkova, Lenka $u CLIP, Dept. of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000189808441
- 700 1_
- $a Koblihova, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Markova, Marketa Stastna $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Benesova, Adela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Polivkova, Vaclava $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Zackova, Daniela $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Roeder, Ingo $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany $u National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany $1 https://orcid.org/http://orcid.org/0000000267410608
- 700 1_
- $a Glauche, Ingmar $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany $1 https://orcid.org/http://orcid.org/0000000225241199
- 700 1_
- $a Ernst, Thomas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany $1 https://orcid.org/http://orcid.org/000000032147489X
- 700 1_
- $a Hochhaus, Andreas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany $1 https://orcid.org/http://orcid.org/0000000306260834
- 700 1_
- $a Polakova, Katerina Machova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000273985555
- 700 1_
- $a Cross, Nicholas C P $u Faculty of Medicine, University of Southampton, Southampton, UK. ncpc@soton.ac.uk $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK. ncpc@soton.ac.uk $1 https://orcid.org/http://orcid.org/0000000154812555
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 7 (2022), s. 1879-1886
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35676453 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100152 $b ABA008
- 999 __
- $a ok $b bmc $g 1854854 $s 1176636
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 36 $c 7 $d 1879-1886 $e 20220608 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20221017
